skip to content »

Department of Pharmacology

Houston, Texas

BCM students are involved in research.
not shown on screen

William Edwin Fann, M.D.

Photo William FannProfessor

Department of Pharmacology

Research Interest:

Side Effects and Interactions of Psychotropic Compounds

Dr. Fann is the founder and principal coordinator of the Texas Medical Center's Clinical Pharmacology Consortium, one of the medical center's most exciting new initiatives in basic science and clinical care. The Clinical Pharmacology Consortium provides an arena for scientists and clinicians from many medical specialties to meet in weekly seminars and smaller study groups to exchange the latest information in the science and clinical application of the latest developments in all areas of pharmacology. The interaction among medical specialists fosters novel ideas, stimulates new research, and helps to generate cooperative inter-institutional and interdisciplinary grant applications for the furtherance of additional research in clinical pharmacology. The consortium also offers an inter-institutional elective in pharmacology and therapeutics.

Dr. Fann's own career has been centered in study of the side effects and interactions of psychotropic compounds, many of which can generate an abundance of clinical complications even as they effectively resolve the target psychiatric symptoms. Dr. Fann's laboratory has created as its focus the study of cardiovascular and neurological effects of psychotropics, particularly in developing predictors for drug-induced movement disorders and potentially fatal cardiac responses to the compounds used to treat the major psychiatric diseases.

Selected Publications:

  1. Sanders AR, Rincon-Limas DE, Chakraborty R, Grandchamp B, Hamilton JD, Fann WE and Patel PI: (1992) Association between genetic variation at the porphobilinogen deaminase gene and schizophrenia. Schizophrenia Research, 8: 221-221.
  2. Nimgaonkar VL, Sanders AR, Fann WE, Zhang XR and Patel PI: (1996) Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples. Amer. J. of Medical Genetics. 67: 505-514.
  3. Fann WE with Olanzapine HGAD Study Group: (1996) Olanzapine vs. placebo vs. haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14: 111-123.
  4. Fann WE: Pharmacology. (1996) IN, Encyclopedia of Gerontology (Ed, Birren, James E.) Academic Press, San Diego, CA. 295-306.

E-mail this page to a friend